Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 4, 2008, Pages 211-223

  Umehara, K I ^a   Susaki, Y ^a   Van Teylingen, R H J ^b   Neat, J N ^c   Ndikum Moffor, F ^c   Noguchi, K ^a   Usui, T ^a   Parkinson, A ^c   Kamimura, H ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

^c XenoTech LLC   (United States)

Author keywords

CYP2D6; CYP3A4 5; Drug drug interaction; Induction; YM758

Indexed keywords

AS 203631300; CARDIOVASCULAR AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; KETOCONAZOLE; METOPROLOL; MIDAZOLAM; N [2 [ 3 (6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBONYL)PIPERIDINO]ETHYL] 4 FLUOROBENZAMIDE; NIFEDIPINE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RITONAVIR; UNCLASSIFIED DRUG; YM 394111; YM 394112; YM 758;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; LIVER CELL CULTURE; LIVER MICROSOME METABOLISM;

EID: 59949098046     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190875     Document Type: Article

References (15)

1. Bucchi A., Barbuti A., Barascotti M., DiFrancesco D. (2007): Heart rate reduction via selective 'funny' channel blockers. Curr. Opin. Pharmacol., 7, 208-213.
2. Indolfi C., Guth B.D., Miura T., Miyazaki S., Schulz R., Ross J Jr. (1989): Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation, 80, 983-993.
3. Roth W., Bauer E., Heinzel G., Cornelissen P.J., van Tol R.G., Jonkman J.H., Zuiderwijk P.B. (1993): Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after i.v. infusion and oral administration to healthy subjects. J. Pharma. Sci., 82, 99-106.
4. Umehara K.I., Seya K., Sonoda T., Nakamura E., Noguchi K., Usui T., Kamimura H. (2008a): Comparative evaluation of absorption, distribution, and excretion of YM758, a novel If channel inhibitor, between albino and non-albino rats. Xenobiotica, 38, 527-539.
5. Umehara K., Iwai M., Adachi Y., Usui T., Iwatsubo T., Kamimura H. (2008b): Hepatic uptake and excretion of YM758, a novel If channel inhibitor, in rats and humans. Drug Metab. Pharmacokinet., 36, 1030-1038.
6. No authors listed. (2007): Ivabradine: new drug. Best avoided in stable angina. Prescrire Int., 16: 53-56.
7. Ragueneau I., Laveille C., Jochemsen R., Resplandy G., Funck-Brentano C., Jaillon P. (1998): Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin. Pharmacol. Ther., 64, 192-203.
8. Pearce R.E., McIntyre C.J., Madan A., Sanzgiri U., Draper A.J., Bullock P.L., Cook D.C., Burton L.A., Latham J., Nevins C., Parkinson A. (1996): Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys., 331, 145-169.
9. Robertson P., DeCory H.H., Madan A., Parkinson A. (2000): In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab. Dispos., 28, 664-671.
10. Gonzalez F.J. (1988): The molecular biology of cytochrome P450s. Pharmacol. Rev., 40, 243-288.
11. Czerwinski M., Opdam P., Madan A., Carroll K., Mudra D.R., Gan L.L., Luo G., Parkinson A. (2002): Analysis of CYP mRNA expression by branched DNA technology. Meth. Enzymol., 357, 170-179.
12. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. (1985): Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76-85.
13. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A.; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003): The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 31, 815-832.
14. Piscitelli S.C., Goss T.F., Wilton J.H., D'Andrea D.T., Goldstein H., Schentag J.J. (1991): Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob. Agents Chemother., 35, 1765-1771.
15. Campbell T.J, Williams K.M. (1998): Therapeutic drug monitoring: antiarrhythmic drugs. Br. J. Clin. Pharmacol., 46, 307-319.